随机控制的第三期研究,比较单独的化疗与转换手术,在初始无法切除的cStage IVB或pStage IV胃癌患者对化疗有显著反应后 (JCOG2301,转换研究)
Ryosuke Kita1, Itaru Yasufuku2, Naoki Takahashi3
1Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Japanese journal of clinical oncology
|December 18, 2024
概括
这项研究调查了化疗后的手术是否可以改善第四阶段胃癌患者的存活率. 它比较了转化手术加化学疗法和化学疗法单独在不可切除的病例.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 第四期胃癌通常接受缓解化疗,结果不佳.
- 迫切需要针对不可切除的第四期胃癌有效的治疗策略.
- 在不可切除的第四阶段胃癌中,局部治疗 (包括手术) 的作用仍然存在争议.
研究的目的:
- 为了评估缓和化疗后转化手术的额外益处,与单独的化疗相比.
- 评估转化手术对不可切除的第四阶段胃癌患者的整体存活时间的影响.
- 为优化晚期胃癌治疗策略提供证据.
主要方法:
- 随机的第三阶段试验设计.
- 在日本63个机构招募了126名患者.
- 转换性手术加化学疗法与单独化学疗法的比较,这些患者对化学疗法有显著的反应.
主要成果:
- 目前正在收集总体存活率和治疗疗效的数据.
- 这项研究旨在确定转换手术是否提供了生存优势.
- 结果将为高级胃癌管理的临床决策提供信息.
结论:
- 这项研究将澄清转化手术在不可切除的第四阶段胃癌中的作用.
- 预计这些发现将指导晚期胃癌的未来治疗方案.
- 这项研究解决了胃癌治疗的关键未满足的需求.
更多相关视频
12:34Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
Published on: January 3, 2020
16.5K
03:32Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
Published on: December 27, 2024
622
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...